Skip to Content Facebook Feature Image

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

News

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing
News

News

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

2024-04-11 20:30 Last Updated At:20:51

WALTHAM, Mass.--(BUSINESS WIRE)--Apr 11, 2024--

Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium (CTS OpTmizer One SFM)*, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. As a result, cell therapy manufacturers can use CTS OpTmizer One SFM to help optimize their workflows and get T cell therapies to patients faster.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411707187/en/

CTS OpTmizer One SFM’s ready-to-use, one-part medium can help cell therapy manufacturers scale their manufacturing from process development to clinical trials and commercial manufacturing while maintaining consistent performance. As part of the cell expansion process, CTS OpTmizer One SFM delivers high cell viability, improved growth and maintains early memory T cell phenotype. In addition, the AOF formulation can help in mitigating risk by reducing opportunities for contamination or inconsistency due to animal-origin (AO) components.

The ability to more-rapidly expand less-differentiated T cells to reach a desired dose can help manufacturers shorten the time to treatment, lower manufacturing costs, increase patient access, and enhance therapeutic efficacy.

OpTmizer One SFM’s ready-to-use, one-part medium advances T cell expansion and cell growth while helping cell therapy manufacturers improve overall drug function for both autologous and allogeneic therapies, when compared to other leading AOF T cell media.

“CAR T-cell therapies have emerged as a highly impactful treatment option for blood cancers, helping cure patients who have not responded to traditional therapies,” said Tiffani Manolis, vice president and general manager of Thermo Fisher’s Cell Culture and Cell Therapy business. “CTS OpTmizer One SFM and our entire Cell Therapy Systems portfolio of products were designed to help cell therapy manufacturers overcome speed, safety and cost challenges to help realize the true potential of these therapies and give new hope to patients around the world.”

Workflows featuring CTS OpTmizer One SFM display a high level of consistency across small and large scales and various culture vessels, such as G‑Rex™ plates, rocking motion bioreactors and stirred tank bioreactors. This flexibility allows CTS OpTmizer One SFM to be leveraged in both autologous and allogeneic workflows. Available as a catalog product in 1 L bottles and 1 L, 5 L, and 10 L bioprocess containers, CTS OpTmizer One SFM is compatible with closed automated instruments such as the Gibco™ CTS™ DynaCellect™ Magnetic Separation System and the Gibco™ CTS™ Rotea Counterflow Centrifugation System.

The CTS OpTmizer One SFM expands Thermo Fisher Scientific’s Gibco Cell Therapy Systems (CTS) portfolio of products. Individually and as a platform, the Gibco CTS portfolio deliver flexibility, efficiency, productivity and scalability across the cell therapy manufacturing workflow. The Gibco CTS portfolio of cell and gene therapy products are GMP manufactured, safety tested and backed by regulatory documentation to help customers transition from discovery through clinical and commercial manufacturing.

To learn more about Gibco™ CTS™ OpTmizer One, please visit Thermo Fisher's media for cell therapy page.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

* For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals

Thermo Fisher Scientific has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. (Photo: Business Wire)

Thermo Fisher Scientific has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. (Photo: Business Wire)

Next Article

Putin says he would like to meet Trump but preparations are ongoing

2025-02-19 22:26 Last Updated At:22:30

KYIV, Ukraine (AP) — Russian President Vladimir Putin said Wednesday he would like to meet with U.S. President Donald Trump but the meeting needs to be prepared to make it productive.

“I would like to have a meeting, but it needs to be prepared so that it brings results,” Putin said in televised remarks. He added that he would be “pleased” to meet Trump.

He hailed the talks between senior Russian and U.S. officials in Riyadh, Saudi Arabia, on Tuesday, noting that the parties agreed to restore the tattered diplomatic relations.

Putin also said that Trump has acknowledged that the Ukrainian settlement could take longer than he had initially hoped.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.

KYIV, Ukraine (AP) — Ukrainian President Volodymyr Zelenskyy accused U.S. President Donald Trump on Wednesday of living in a Russian-made “disinformation space,” pointed comments that risk further souring relations with Washington as the American leader pushes for an end to the war.

Zelenskyy said he “would like Trump’s team to be more truthful” in his first response to a series of striking claims the U.S. president made the previous day, including suggesting that Kyiv was to blame for the war, which enters its fourth year next week.

Russia’s army crossed the border on Feb. 24, 2022, in an all-out invasion that Putin sought to justify by saying it was needed to protect civilians in eastern Ukraine and prevent the country from joining NATO. Ukraine and its allies denounced it as an unprovoked act of aggression.

The comments from Trump and Zelenskyy were a remarkable back-and-forth between leaders of two countries that have been staunch allies in recent years under Trump’s predecessor, as the U.S. provided crucial military equipment to Kyiv to fend off the invasion and used its political weight to defend Ukraine and isolate Russia on the world stage.

The Trump administration has started charting a new course, reaching out to Russia and pushing for a peace deal. Zelenskyy spoke shortly before he was expected to meet with Keith Kellogg, the U.S. special envoy for Ukraine and Russia as part of the administration's recent diplomatic blitz.

Ukraine and its European supporters have expressed concern that they weren’t invited to the talks between top American and Russian diplomats in Saudi Arabia — amid larger worries that the deal taking shape could be unfavorable to Kyiv.

At a news conference Tuesday, Trump showed little patience for Ukraine’s objections to being excluded from the talks. He also said, without providing the source, that Zelenskyy’s approval rating stood at 4%, while telling reporters that Ukraine “should have never started” the war and “could have made a deal” to prevent it.

Zelenskyy replied in his own news conference Wednesday that “we have seen this disinformation. We understand that it is coming from Russia.” He said that Trump “lives in this disinformation space.”

Zelenskyy said he hoped Kellogg would walk through Kyiv and “ask (Ukrainians) if they trust their president? Do they trust Putin? Let him ask about Trump, what they think after the statements made by their president."

Russian state TV and other state-controlled media reacted with glee to what they portrayed as Trump’s cold shoulder to Zelenskyy.

“Trump isn’t even trying to hide his irritation with Zelenskyy,” the Rossiya channel said at the top of its newscast.

“Trump steamrolled Zelenskyy for his complaints about the talks with Russia,” the daily Komsomolskaya Pravda said.

Trump also suggested Ukraine ought to hold elections, which have been postponed due to the war and the consequent imposition of martial law, in accordance with the Ukrainian Constitution.

Zelenskyy also referred to “the story” that 90% of all aid received by Ukraine comes from the United States.

He said that, for instance, about 34% of all weapons in Ukraine are domestically produced and over 30% of support comes from Europe.

The battlefield has brought more grim news for Ukraine in recent months. A relentless onslaught in eastern areas by Russia's bigger army is grinding down Ukrainian forces, who are slowly but steadily being pushed backward at some points on the 1,000-kilometer (600-mile) front line.

American officials have signaled that Ukraine’s hopes of joining NATO in order to ward off Russian aggression after reaching a possible peace agreement won’t happen. Zelenskyy says any settlement will require U.S. security commitments to keep Russia at bay.

“We understand the need for security guarantees,” Kellogg said in comments carried by Ukrainian public broadcaster Suspilne Novyny on his arrival at Kyiv's train station.

“It’s very clear to us the importance of the sovereignty of this nation and the independence of this nation as well. ... Part of my mission is to sit and listen,” the retired three-star general said.

Kellogg said he would convey what he learns on his visit to Trump and Secretary of State Marco Rubio to “ensure that we get this one right.”

Follow AP’s coverage of the war in Ukraine at https://apnews.com/hub/russia-ukraine

Ukraine's President Volodymyr Zelensky gives a press conference in Kyiv, Wednesday, Feb. 19, 2025. (Tetiana Dzhafarova/Pool Photo via AP)

Ukraine's President Volodymyr Zelensky gives a press conference in Kyiv, Wednesday, Feb. 19, 2025. (Tetiana Dzhafarova/Pool Photo via AP)

From right, U.S. Special Envoy Keith Kellogg, United States Vice-President JD Vance and United States Secretary of State Marco Rubio meet with Ukraine's President Volodymyr Zelenskyy on the sidelines of the Munich Security Conference in Munich, Germany, Friday, Feb. 14, 2025. (AP Photo/Matthias Schrader)

From right, U.S. Special Envoy Keith Kellogg, United States Vice-President JD Vance and United States Secretary of State Marco Rubio meet with Ukraine's President Volodymyr Zelenskyy on the sidelines of the Munich Security Conference in Munich, Germany, Friday, Feb. 14, 2025. (AP Photo/Matthias Schrader)

Recommended Articles